- Home
- AKA vs LUNG Comparison
AKA vs LUNG Comparison
Compare AKA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- LUNG
- Stock Information
- Founded
- AKA 2018
- LUNG 1995
- Country
- AKA United States
- LUNG United States
- Employees
- AKA N/A
- LUNG N/A
- Industry
- AKA Catalog/Specialty Distribution
- LUNG Industrial Specialties
- Sector
- AKA Consumer Discretionary
- LUNG Health Care
- Exchange
- AKA Nasdaq
- LUNG Nasdaq
- Market Cap
- AKA 110.4M
- LUNG 124.0M
- IPO Year
- AKA 2021
- LUNG 2020
- Fundamental
- Price
- AKA $11.08
- LUNG $2.87
- Analyst Decision
- AKA Buy
- LUNG Buy
- Analyst Count
- AKA 4
- LUNG 6
- Target Price
- AKA $22.50
- LUNG $11.53
- AVG Volume (30 Days)
- AKA 8.2K
- LUNG 318.2K
- Earning Date
- AKA 08-06-2025
- LUNG 07-30-2025
- Dividend Yield
- AKA N/A
- LUNG N/A
- EPS Growth
- AKA N/A
- LUNG N/A
- EPS
- AKA N/A
- LUNG N/A
- Revenue
- AKA $586,514,000.00
- LUNG $87,473,000.00
- Revenue This Year
- AKA $6.60
- LUNG $18.02
- Revenue Next Year
- AKA $4.14
- LUNG $18.17
- P/E Ratio
- AKA N/A
- LUNG N/A
- Revenue Growth
- AKA 8.09
- LUNG 19.84
- 52 Week Low
- AKA $7.00
- LUNG $2.50
- 52 Week High
- AKA $32.25
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- AKA 45.23
- LUNG 39.07
- Support Level
- AKA $10.71
- LUNG $2.62
- Resistance Level
- AKA $11.59
- LUNG $2.88
- Average True Range (ATR)
- AKA 0.71
- LUNG 0.17
- MACD
- AKA -0.05
- LUNG 0.05
- Stochastic Oscillator
- AKA 33.20
- LUNG 39.68
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.